RT Journal Article
SR Electronic
T1 New arguments for double action release active drugs in preparation for vaccination against pneumococcus among children with chronic sites of infection in nasopharynx
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA1270
DO 10.1183/13993003.congress-2016.PA1270
VO 48
IS suppl 60
A1 Vera Vavilova
A1 Alexander Vavilov
A1 Asya Cherkaeva
A1 Irina Nechaeva
A1 Alla Evstratenko
YR 2016
UL http://erj.ersjournals.com/content/48/suppl_60/PA1270.abstract
AB Aim: To evaluate the results of the prospective comparative study on efficacy of use of Anaferon for children in preparation for vaccination against pneumococcus among 994 children (aged from 2 to 5 years) with chronic nasopharyngeal diseases.Materials: The study period: December 2011 to April 2015. Presents a comparative analysis of the incidence rate of respiratory and ENT-infections. In addition, the total number of cell elements and the main cell population ratio were analyzed, lysozyme activity and secretory immunoglobulin A (slgA) in nasal secretions were evaluated.Results: It was shown that use of Anaferon for children during a 1 month period beginning 10 days prior to vaccination increases vaccination coverage among children. The group taking Anaferon for children showed that over a year period the incidence rate of acute respiratory infection was 1.2 times less (p <0,022), pneumonia — 1.4 times less (p =0,354), acute bronchitis —1.2 times less (p =0,374), acute otitis media and chronic maxillary sinusitis — 1.2 (p =0,467) and 1.5 times less (p =0,279) than in the control group. The vaccination and release active drugs also showed a positive impact on the local protective factors of the upper respiratory tract such as lysozyme, slgA, cell elements of nasal secretions.Conclusions: The study showed good tolerability of Anaferon for children and PCV13, safety of its use among children with chronic nasopharyngeal diseases.